1. Research
lady writing on dry erase board

Cancer Immunology

Cancer Immunology

The Cancer Immunology (CI) program has three main scientific goals.

  1. Identify genomic, molecular and cellular pathways underlying immune dysfunction in the tumor microenvironment. CI members use preclinical model systems, CRISPR screens and human tumor lesions to identify novel mechanisms/targets underlying immune dysregulation and prioritize targets of immunotherapy resistance/response ultimately tested in novel clinical trials.
  2. Develop scientifically-based strategies that will improve and/or expand current immunotherapeutic platforms, and identify immune biomarkers of risk and response to treatment. The overarching goal is to progress discoveries that are made into innovative clinical trials to test and validate proposed correlates of resistance and response.
  3. Develop novel clinically applicable immune targets to effectively control or eradicate cancers.

Specific Aims

  • Investigate immune dysregulation in the tumor microenvironment
  • Develop and interrogate models to reverse immune dysfunction and restore immune balance
  • Validate correlates of response in cancer patients receiving immunotherapy
Find A Clinical Trial Make a Gift Discover Careers

Cancer Immunology Research Program Leaders

Nina Bhardwaj, MD, PhD
Nina Bhardwaj, MD, PhD

Clinical Research Support Unit Medical Director, Immunotherapy

Miriam Merad, MD, PhD
Miriam Merad, MD, PhD
CHAIR | Immunology & Immunotherapy
DIRECTOR, PRECISION IMMUNOLOGY INSTITUTE
PROFESSOR | Immunology & Immunotherapy
PROFESSOR | Oncological Sciences
PROFESSOR | Medicine, Hematology and Medical Oncology
PROFESSOR | Dermatology

Members

AT A GLANCE

Cancer Immunology Research

2318
Publications
1830
Press/Media

23 Researchers

Researchers Image 1
Researchers Image 2
Researchers Image 5
Researchers Image 6
View All Researchers

Recent Publications

Phase II study on the safety and immunogenicity of single-dose intramuscular or intranasal administration of the AVX/COVID-12 “Patria” recombinant Newcastle disease virus vaccine as a heterologous booster against COVID-19 in Mexico. Vaccine

TRIM65 regulates innate immune signaling by enhancing K6-linked ubiquitination of IRF3 and its chromatin recruitment. Cell Reports

Unveiling the hidden network of STING's subcellular regulation. Cell Systems

View Full Details

Moving the Field Forward

Find out how we collaborate to address cancer’s most complex challenges.

Stuart A. Aaronson, MD: 2024 Jacobi Medallion Recipient
Thomas Marron, MD, PhD – AACR Annual Meeting 2023
Ramon Parsons, MD, PhD: 2023 Jacobi Medallion Recipient
2022 Distinguished Scholar Award - Dr. Alice Kamphorst
Center of Excellence: Liver and Bile Duct Cancer
Tisch Cancer Institute COVID-19 Research Briefing: May 14, 2020
Watch Videos

Resources For You

Cancer Centers of Excellence
Patient Care
Oncological Sciences
Division of Hematology and Medical Oncology
Residencies and Fellowships
Shared Resources

Contact Us

The Tisch Cancer Institute

One Gustave L. Levy Place

Box 1128

New York, NY 10029-6574

Christine Ponder, PhD, MPA
Director, Research Administration

212-659-5600
Email

Patient Information
The Clinical Research Support Unit

212-824-7391
Email